SCHEMBL906468

SCHEMBL906468

CC([NH])=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5020802 0.75
SCHEMBL4877351 0.72
SCHEMBL7786444 0.72
SCHEMBL31115 0.72
SCHEMBL8948 0.67
SCHEMBL5861030 0.67 FFAR3 (0.40)
SCHEMBL2723641 0.67
SCHEMBL1275690 0.67
SCHEMBL1425834 0.67
SCHEMBL8201994 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023220744-A2 SINGLE-STRANDED LOOP OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. (US) 2023-11-16 WO claimed
WO-2023152371-A1 GUIDE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING IN THE TREATMENT OF HYPERCHOLESTEROLEMIA PROQR THERAPEUTICS II B.V. (NL) 2023-08-17 WO claimed
US-20230257745-A1 Circular siRNAs BANK OF AMERICA, N.A. 2023-08-17 US claimed
US-20230039928-A1 Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease PROQR THERAPEUTICS II B.V. (NL) 2023-02-09 US claimed
WO-2022011214-A1 CIRCULAR SIRNAS ALNYLAM PHARMACEUTICALS, INC. (US) 2022-01-13 WO claimed
EP-3919619-A1 MULTI-TARGETED SINGLE ENTITY CONJUGATES Alnylam Pharmaceuticals, Inc. (US) 2021-12-08 EP claimed
WO-2021130313-A1 ANTISENSE OLIGONUCLEOTIDES FOR NUCLEOTIDE DEAMINATION IN THE TREATMENT OF STARGARDT DISEASE PROQR THERAPEUTICS II B.V. (NL) 2021-07-01 WO claimed
CN-110055057-B Column [5] arene-based supramolecular polymer gel, and synthesis and application thereof 西北师范大学 2021-03-23 CN claimed
EP-3324980-A1 MULTI-TARGETED SINGLE ENTITY CONJUGATES Alnylam Pharmaceuticals, Inc. (US) 2018-05-30 EP claimed
WO-2017015109-A1 MULTI-TARGETED SINGLE ENTITY CONJUGATES ALNYLAM PHARMACEUTICALS, INC. (US) 2017-01-26 WO claimed
EP-0205005-B1 NEW BIOLOGICALLY ACTIVE FLUORESCENT CYCLIC NUCLEOTIDES UNIVERSITA' DEGLI STUDI DI PARMA (IT) 1992-05-13 EP claimed
US-4748165-A ANTISECRETORY AGENTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-05-31 US claimed
EP-0248597-A2 Phospholipase A2 inhibitors and methods of synthesis ORTHO PHARMACEUTICAL CORPORATION (US) 1987-12-09 EP claimed
EP-0060697-B1 HETEROCYCLIC DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-12-30 EP claimed
EP-0205005-A2 New biologically active fluorescent cyclic nucleotides UNIVERSITA' DEGLI STUDI DI PARMA (IT) 1986-12-17 EP claimed
EP-0067508-B1 AMIDINE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-10-30 EP claimed
EP-0067508-A1 Amidine derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-12-22 EP claimed
EP-0060697-A1 Heterocyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-22 EP claimed
US-4263037-A 5-Cyano-2,3-dihydrobenzofurans useful as herbicides FISONS LIMITED (GB) 1981-04-21 US claimed
EP-0007719-A2 Cyanbenzofuran derivatives, processes for their preparation and their use in herbicidal compositions; cyanobenzene, benzodioxepine, benzodioxaphosphepine and benzodioxathiepine derivatives FBC LIMITED (GB) 1980-02-06 EP claimed